What happened
Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation
SourceElsevier BVpublicationBiotech
Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation
Publication signal: Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceElsevier BVLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceElsevier BVLinked output
Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translationpaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation
Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation
Clinical and Regulatory
Controlled AISci Stage A topic for Clinical and Regulatory.
Timeline
- publicationOral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation